Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gaemers

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
ACS Applied Materials & Interfaces|December 23, 2016
Property Self-Optimization During Wear of MoS<sub>2</sub>Rui Hao, Aleksander A Tedstone, David J Lewis, et al.
American Journal of Hematology|September 29, 2018
Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trialElena Lukina, Nora Watman, Marta Dragosky, et al.
Endocrinology|September 29, 1998
The effect of 9-cis-retinoic acid on proliferation and differentiation of a spermatogonia and retinoid receptor gene expression in the vitamin A-deficient mouse testisI C Gaemers, E Sonneveld, A M van Pelt, et al.
Molecular Genetics and Metabolism|January 24, 2018
Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: The Phase 3, randomized, double-blind EDGE trialJoel Charrow, Cristina Fraga, Xuefan Gu, et al.
Developmental Biology|December 3, 2014
Hepatic Notch2 deficiency leads to bile duct agenesis perinatally and secondary bile duct formation after weaningFarah A Falix, Víola B Weeda, Wilhelmina T Labruyere, et al.
Molecular Genetics and Metabolism Reports|October 11, 2016
Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trialRebecca Pleat, Timothy M Cox, T Andrew Burrow, et al.
Biochimica Et Biophysica Acta|February 16, 2013
Prevention and reversal of hepatic steatosis with a high-protein diet in miceSonia C Garcia-Caraballo, Tine M Comhair, Fons Verheyen, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|June 14, 2005
Is bridging to transplantation with a left ventricular assist device a risk factor for transplant coronary artery disease?Branislav Radovancevic, Alessandro Golino, Bojan Vrtovec, et al.
ACS Applied Materials & Interfaces|September 1, 2015
Mechanical Properties of Molybdenum Disulfide and the Effect of Doping: An in Situ TEM StudyAleksander A Tedstone, David J Lewis, Rui Hao, et al.
Brain : a Journal of Neurology|October 18, 2022
Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trialRaphael Schiffmann, Timothy M Cox, Jean-François Dedieu, et al.
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
ACS Applied Materials & Interfaces|December 23, 2016
Property Self-Optimization During Wear of MoS<sub>2</sub>Rui Hao, Aleksander A Tedstone, David J Lewis, et al.
American Journal of Hematology|September 29, 2018
Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trialElena Lukina, Nora Watman, Marta Dragosky, et al.
Endocrinology|September 29, 1998
The effect of 9-cis-retinoic acid on proliferation and differentiation of a spermatogonia and retinoid receptor gene expression in the vitamin A-deficient mouse testisI C Gaemers, E Sonneveld, A M van Pelt, et al.
Molecular Genetics and Metabolism|January 24, 2018
Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: The Phase 3, randomized, double-blind EDGE trialJoel Charrow, Cristina Fraga, Xuefan Gu, et al.
Developmental Biology|December 3, 2014
Hepatic Notch2 deficiency leads to bile duct agenesis perinatally and secondary bile duct formation after weaningFarah A Falix, Víola B Weeda, Wilhelmina T Labruyere, et al.
Molecular Genetics and Metabolism Reports|October 11, 2016
Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trialRebecca Pleat, Timothy M Cox, T Andrew Burrow, et al.
Biochimica Et Biophysica Acta|February 16, 2013
Prevention and reversal of hepatic steatosis with a high-protein diet in miceSonia C Garcia-Caraballo, Tine M Comhair, Fons Verheyen, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|June 14, 2005
Is bridging to transplantation with a left ventricular assist device a risk factor for transplant coronary artery disease?Branislav Radovancevic, Alessandro Golino, Bojan Vrtovec, et al.
ACS Applied Materials & Interfaces|September 1, 2015
Mechanical Properties of Molybdenum Disulfide and the Effect of Doping: An in Situ TEM StudyAleksander A Tedstone, David J Lewis, Rui Hao, et al.
Brain : a Journal of Neurology|October 18, 2022
Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trialRaphael Schiffmann, Timothy M Cox, Jean-François Dedieu, et al.
Pageof 7